...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population‐Based Cohort Study
【24h】

Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population‐Based Cohort Study

机译：雄激素剥夺治疗使用增加了前列腺癌患者心力衰竭的风险：基于人群的队列研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract The aim of this study was to investigate the relationship between androgen deprivation therapy and heart failure among prostate cancer patients. This cohort study used the data from the Taiwan Longitudinal Health Insurance Database 2005. In the full cohort study, we identified 1244 prostate cancer patients who had received androgen deprivation therapy as the study cohort and 1806 prostate cancer patients who did not receive androgen deprivation therapy as the comparison cohort. To eliminate potential bias, we performed a propensity score‐matched cohort study. Each prostate cancer patient was tracked for 1 year from the index date to ascertain whether they were subsequently diagnosed with heart failure. In the full cohort study, incidence rates of heart failure per 100 person‐years within the 1‐year follow‐up period were 4.00 (95%CI, 2.95‐5.30) and 1.89 (95%CI, 1.30‐2.66) for androgen deprivation therapy users and nonusers, respectively. In addition, the multivariable Cox regression indicated that the hazard ratio (HR) of heart failure among androgen deprivation therapy users was 1.72 (95%CI, 1.08‐2.73) compared with those androgen deprivation therapy nonusers. In the propensity score‐matched cohort study, the adjusted HR for heart failure among androgen deprivation therapy users was 1.92 (95%CI, 1.15‐3.18) compared with propensity score‐matched nonusers. In conclusion, this study found that androgen deprivation therapy users had a higher risk of heart failure than nonusers among prostate cancer patients in both the full cohort study and the propensity score‐matched study.
机译：摘要本研究的目的是调查前列腺癌患者中雄激素剥夺治疗与心力衰竭之间的关系。该队列研究使用了来自台湾纵向健康保险数据库2005年的数据。在全面的队列研究中，我们确定了1244名接受雄激素剥夺治疗的前列腺癌患者作为研究队列和1806例未接受雄激素剥夺治疗的前列腺癌患者比较队列。为了消除潜在的偏见，我们进行了倾向分数匹配的队列研究。从指数日期跟踪每个前列腺癌患者1年，以确定它们是否随后被诊断为心力衰竭。在全面的队列研究中，每100人患者随访期内每100人的心力衰竭的发病率为4.00（95％CI，2.95-5.30）和1.89（95％CI，1.30-2.66），用于雄激素剥夺治疗用户和非用户。此外，与那些雄激素剥夺治疗非用户相比，多变量的Cox回归表明，雄激素剥夺治疗用户之间的心力衰竭的危险比（HR）为1.72（95％CI，1.08-2.73）。在倾向分数匹配的队列研究中，与博登剥夺治疗用户之间的心力衰竭的调整后的HR为1.92（95％CI，1.15-3.18），与倾向分数匹配的非用户相比。总之，本研究发现，雄激素剥夺治疗用户在全面队列研究中的前列腺癌患者中的心力衰竭风险较高，并且在全面的队列研究和倾向分数匹配的研究中的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号